Header

UZH-Logo

Maintenance Infos

Vaccination against the Epstein–Barr virus


Rühl, Julia; Leung, Carol S; Münz, Christian (2020). Vaccination against the Epstein–Barr virus. Cellular and Molecular Life Sciences, 77(21):4315-4324.

Abstract

Epstein–Barr virus (EBV) was the first human tumor virus being discovered and remains to date the only human pathogen that can transform cells in vitro. 55 years of EBV research have now brought us to the brink of an EBV vaccine. For this purpose, recombinant viral vectors and their heterologous prime-boost vaccinations, EBV-derived virus-like particles and viral envelope glycoprotein formulations are explored and are discussed in this review. Even so, cell-mediated immune control by cytotoxic lymphocytes protects healthy virus carriers from EBV-associated malignancies, antibodies might be able to prevent symptomatic primary infection, the most likely EBV-associated pathology against which EBV vaccines will be initially tested. Thus, the variety of EBV vaccines reflects the sophisticated life cycle of this human tumor virus and only vaccination in humans will finally be able to reveal the efficacy of these candidates. Nevertheless, the recently renewed efforts to develop an EBV vaccine and the long history of safe adoptive T cell transfer to treat EBV-associated malignancies suggest that this oncogenic γ-herpesvirus can be targeted by immunotherapies. Such vaccination should ideally implement the very same immune control that protects healthy EBV carriers.

Abstract

Epstein–Barr virus (EBV) was the first human tumor virus being discovered and remains to date the only human pathogen that can transform cells in vitro. 55 years of EBV research have now brought us to the brink of an EBV vaccine. For this purpose, recombinant viral vectors and their heterologous prime-boost vaccinations, EBV-derived virus-like particles and viral envelope glycoprotein formulations are explored and are discussed in this review. Even so, cell-mediated immune control by cytotoxic lymphocytes protects healthy virus carriers from EBV-associated malignancies, antibodies might be able to prevent symptomatic primary infection, the most likely EBV-associated pathology against which EBV vaccines will be initially tested. Thus, the variety of EBV vaccines reflects the sophisticated life cycle of this human tumor virus and only vaccination in humans will finally be able to reveal the efficacy of these candidates. Nevertheless, the recently renewed efforts to develop an EBV vaccine and the long history of safe adoptive T cell transfer to treat EBV-associated malignancies suggest that this oncogenic γ-herpesvirus can be targeted by immunotherapies. Such vaccination should ideally implement the very same immune control that protects healthy EBV carriers.

Statistics

Citations

Dimensions.ai Metrics
3 citations in Web of Science®
4 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 04 Feb 2021
1 download since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute of Experimental Immunology
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Scopus Subject Areas:Life Sciences > Molecular Medicine
Life Sciences > Molecular Biology
Life Sciences > Pharmacology
Life Sciences > Cellular and Molecular Neuroscience
Life Sciences > Cell Biology
Uncontrolled Keywords:Molecular Medicine, Cell Biology, Molecular Biology, Pharmacology, Cellular and Molecular Neuroscience
Language:English
Date:1 November 2020
Deposited On:04 Feb 2021 14:15
Last Modified:05 Feb 2021 21:05
Publisher:Springer
ISSN:1420-682X
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1007/s00018-020-03538-3
PubMed ID:32367191
Project Information:
  • : FunderSNSF
  • : Grant ID310030B_182827
  • : Project TitleExcellence Grant - Role of autophagy proteins in endocytosis and exocytosis
  • : FunderSNSF
  • : Grant IDCRSII5_180323
  • : Project TitleNovel virucidal drugs: From basic to in vivo studies
  • : FunderSNSF
  • : Grant IDP300P3_155374
  • : Project TitleDevelopment of viral vectored vaccines for MAGE-expressing tumours

Download

Closed Access: Download allowed only for UZH members

Content: Accepted Version
Filetype: PDF - Registered users only until 4 May 2021
Size: 354kB
View at publisher
Embargo till: 2021-05-04